我们的排名是通过综合多种权威来源的全面数据驱动方法生成的。
我们首先从公司年报（10-K和20-F文件）、证券交易所披露（NYSE、NASDAQ、Euronext、ASX、SZSE）以及Expert Market Research、Fortune Business Insights、IQVIA和Evaluate Pharma等组织的行业研究中收集数据。
每家公司根据四个加权维度进行评估：
• 品牌影响力与全球收入（40%）：来自2025财年文件的全球总收入（美元等值）、净利润率和资产规模
• 类别收入一致性（30%）：来自生物制品、疫苗及相关治疗类别的特定收入
• 供应链安全与制造控制（20%）：自有生产设施数量、国家覆盖范围、员工规模和年产能
• 品牌可见性与市场情绪（10%）：基于搜索引擎存在感、医疗保健提供者情绪和近期研发里程碑的综合评分
数据验证包括交叉引用多个独立来源以及对每个公司简介进行人工编辑审查。排名定期更新，以反映新的财务披露、并购活动以及重大的临床或监管进展。
Our rankings are generated through a comprehensive, data-driven methodology that combines multiple authoritative sources.
We begin by collecting data from company annual reports (10-K and 20-F filings), securities exchange disclosures (NYSE, NASDAQ, Euronext, ASX, SZSE), and industry research from organizations such as Expert Market Research, Fortune Business Insights, IQVIA, and Evaluate Pharma.
Each company is evaluated across four weighted dimensions:
• Brand Influence & Global Revenue (40%): Total global revenue in USD equivalent, net profit margin, and asset scale from FY2025 filings
• Category Revenue Alignment (30%): Revenue specifically from biological products, vaccines, and related therapeutic categories
• Supply Chain Security & Manufacturing Control (20%): Number of owned production facilities, country coverage, workforce size, and annual production capacity
• Brand Visibility & Market Sentiment (10%): Composite score based on search engine presence, healthcare provider sentiment, and recent R&D milestones
Data verification includes cross-referencing multiple independent sources and manual editorial review of each company profile. Rankings are updated periodically to reflect new financial disclosures, M&A activity, and significant clinical or regulatory developments.
生物制品和疫苗行业涵盖研究、开发、生产和分销源自生物体的治疗和预防产品的公司。这些生物制品包括疫苗（针对传染病的预防性免疫）、单克隆抗体（靶向癌症和自身免疫疗法）、重组蛋白（激素、酶和凝血因子）、血液和血浆衍生品（免疫球蛋白、白蛋白、凝血因子）以及前沿技术如mRNA疗法和细胞与基因治疗。
该行业与小分子药物的根本区别在于其制造复杂性。生物制品通常通过活细胞培养（哺乳动物、酵母或细菌）生产，需要严格控制发酵或细胞培养过程、多步纯化以及严格的冷链分销。单个生物制品制造工厂的成本可能高达5亿至20亿美元，建设并验证需要5-7年——这形成了自然进入壁垒，解释了该行业为何集中于大型垂直整合企业。
推动行业增长的关键子领域包括：
• GLP-1/GIP代谢生物制品：增长最快的类别，诺和诺德和礼来在2025年从糖尿病和肥胖治疗中合计收入超过1100亿美元
• 癌症免疫疗法：尤其是默沙东的Keytruda，收入317亿美元，是全球最畅销的单一药品
• 预防性疫苗：来自辉瑞、赛诺菲、葛兰素史克和默沙东的流感、HPV、肺炎球菌、RSV和带状疱疹疫苗
• 血浆制品：CSL Limited的垂直整合血浆采集和分馏网络，服务于危重患者
• mRNA平台技术：BioNTech和Moderna在后疫情时代转向个性化癌症疫苗
全球市场预计到2035年将以超过10%的复合年增长率增长，驱动因素包括人口老龄化、新兴市场疫苗覆盖率扩大以及实现新治疗模式的突破性平台技术。
The biological products and vaccines industry encompasses companies that research, develop, manufacture, and distribute therapeutic and preventive products derived from living organisms. These biologics include vaccines (prophylactic immunization against infectious diseases), monoclonal antibodies (targeted cancer and autoimmune therapies), recombinant proteins (hormones, enzymes, and clotting factors), blood and plasma-derived products (immunoglobulins, albumin, coagulation factors), and cutting-edge modalities such as mRNA therapeutics and cell and gene therapies.
The industry is fundamentally distinguished from small-molecule pharmaceuticals by its manufacturing complexity. Biologics are typically produced through living cell cultures (mammalian, yeast, or bacterial), requiring tightly controlled fermentation or cell culture processes, multi-step purification, and stringent cold chain distribution. A single biologic manufacturing facility can cost $500 million to $2 billion and take 5-7 years to construct and validate—creating natural barriers to entry that explain the industry's concentration among large, vertically integrated players.
Key sub-segments driving industry growth include:
• GLP-1/GIP metabolic biologics: The fastest-growing category, with Novo Nordisk and Eli Lilly generating over $110 billion combined in 2025 from diabetes and obesity treatments
• Cancer immunotherapy: Notably Merck's Keytruda at $31.7 billion, the world's single best-selling pharmaceutical product
• Preventive vaccines: Influenza, HPV, pneumococcal, RSV, and shingles vaccines from Pfizer, Sanofi, GSK, and Merck
• Blood plasma products: CSL Limited's vertically integrated plasma collection and fractionation network serving critical-care patients
• mRNA platform technologies: BioNTech and Moderna's post-pandemic pivot toward individualized cancer vaccines
The global market is projected to grow at a CAGR exceeding 10% through 2035, driven by aging populations, expanding vaccine coverage in emerging markets, and breakthrough platform technologies enabling new therapeutic modalities.
生产能力已成为生物制品行业决定性的竞争差异化因素，“产能即护城河”正在取代传统的专利护城河。最显著的例子是GLP-1药物类别，诺和诺德和礼来已共同承诺超过300亿美元用于生产扩张，因为Ozempic、Wegovy、Mounjaro和Zepbound的需求远超全球所有可用的肽合成和无菌灌装生产能力。
三个结构性转变正在重塑生物制药生产：
• 通过并购实现垂直整合：诺和控股以165亿美元收购Catalent——将全球最大CDMO产能转化为诺和诺德全资拥有的生产资产——代表了对外包模式的根本性否定。礼来通过有机建设而非收购，以210多亿美元的承诺在印第安纳州建设绿地设施，追求相同策略。
• 地缘政治驱动的本土化：辉瑞（36个设施）、GSK（300亿美元美国承诺）、赛诺菲（200亿美元美国承诺）和罗氏（500亿美元美国承诺）都在大幅扩大美国本土生产，受供应链安全担忧和潜在关税风险驱动。
• 平台技术生产：mRNA疫苗（辉瑞/BioNTech）、细胞和基因疗法以及抗体药物偶联物（ADC）各自需要专门的隔离、纯化和质量控制基础设施，这些无法从传统小分子设施改造而来。
对采购和合作策略的影响深远：控制自身生产的公司可以保证重磅产品的供应连续性，在政府招标过程中占据优势，并保护深度嵌入监管文件中的工艺知识产权。依赖CDMO的公司则面临产能分配风险、质量体系协调挑战以及在多客户设施中议价能力下降的问题。
Manufacturing capacity has become the defining competitive differentiator in the biological products industry, with "capacity as moat" replacing traditional patent-based moats. The most dramatic example is the GLP-1 drug class, where Novo Nordisk and Eli Lilly have collectively committed over $30 billion to manufacturing expansion because demand for Ozempic, Wegovy, Mounjaro, and Zepbound far exceeds all available global production capacity for peptide synthesis and sterile fill-finish.
Three structural shifts are reshaping biopharmaceutical manufacturing:
• Vertical integration through M&A: Novo Holdings' $16.5 billion acquisition of Catalent—converting the world's largest CDMO capacity into wholly-owned Novo Nordisk production assets—represents a fundamental rejection of the outsourcing model. Lilly's $21+ billion commitment to Indiana-based greenfield facilities pursues the same strategy through organic buildout rather than acquisition.
• Geopolitical onshoring: Pfizer (36 facilities), GSK ($30 billion US commitment), Sanofi ($20 billion US commitment), and Roche ($50 billion US commitment) are all dramatically expanding US-based production, driven by supply chain security concerns and potential tariff exposure.
• Platform technology manufacturing: mRNA vaccines (Pfizer/BioNTech), cell and gene therapies, and antibody-drug conjugates (ADCs) each require specialized containment, purification, and quality control infrastructure that cannot be repurposed from legacy small-molecule facilities.
The implications for procurement and partnership strategy are profound: companies that control their own manufacturing can guarantee supply continuity for blockbuster products, negotiate from strength in government tender processes, and protect process intellectual property that is deeply embedded in regulatory filings. Companies dependent on CDMOs face capacity allocation risk, quality system alignment challenges, and reduced bargaining power in multi-client facilities.
选择生物制品或疫苗合作伙伴需要评估四个领域，这些领域超越了价格，涉及供应保障、质量体系成熟度和监管记录。智飞生物因过度依赖单一合作伙伴的产品线而遭受灾难性收入中断——损失147亿元人民币——这说明了合作伙伴集中的生存风险。
关键评估标准包括：
• 制造自主性和冗余：合作伙伴是否拥有自己的生产设施（而非通过CDMO外包）？有多少个地理分布的生产基地可以生产相同产品？辉瑞的36个设施网络提供了单工厂制造商无法比拟的冗余。诺和诺德收购的三个Catalent灌装-完成基地提供了跨大洲的并行生产能力。
• 监管合规历史：审查过去五年的FDA 483表格观察项、警告信和EMA GMP不合规声明。疫苗设施因无菌制造要求而面临更严格的审查。默沙东的Gardasil生产设施在数十年的生产中保持了卓越的检查记录。
• 冷链和物流能力：mRNA疫苗需要超低温储存（某些辉瑞/BioNTech产品为-70°C），而血浆产品需要温控分馏和分销。合作伙伴必须展示从工厂到接种点的经过验证的冷链基础设施。
• 管线对齐和技术平台兼容性：评估合作伙伴的制造技术（哺乳动物细胞培养、酵母表达、mRNA-LNP配方、血浆分馏）是否与您的产品要求匹配。GSK对AI驱动的灵活生物制品制造的投资表明其平台适应性，这是传统固定用途设施所缺乏的。
• 财务稳定性和资本承诺：合作伙伴必须维持多年、数十亿美元的制造建设计划。罗氏500亿美元的美国承诺、礼来210亿美元以上的印第安纳投资以及诺和诺德在卡伦堡的持续扩张，展示了生物制品制造合作伙伴所需的财务持久力。
对于政府和公共卫生采购方而言，评估大流行防范能力：合作伙伴能否迅速将生产转向新型病原体？基于细胞和mRNA的疫苗平台相比传统的基于鸡蛋的流感制造，提供了显著更快的毒株变更时间。
Selecting a biological products or vaccine partner requires evaluating four domains that extend beyond price and into supply assurance, quality system maturity, and regulatory track record. The catastrophic revenue disruption experienced by Zhifei Biological—a RMB 14.7 billion loss driven entirely by over-reliance on a single partner's product franchise—illustrates the existential risk of partner concentration.
Critical evaluation criteria include:
• Manufacturing autonomy and redundancy: Does the partner own its production facilities (not contract through CDMOs)? How many geographically distributed sites can produce the same product? Pfizer's 36-facility network provides redundancy that single-plant manufacturers cannot match. Novo Nordisk's three acquired Catalent fill-finish sites provide parallel production capability across continents.
• Regulatory compliance history: Review FDA Form 483 observations, Warning Letters, and EMA GMP non-compliance statements from the past five years. Vaccine facilities face heightened scrutiny due to sterile manufacturing requirements. Merck's Gardasil manufacturing facility has maintained an exemplary inspection record over decades of production.
• Cold chain and logistics capability: mRNA vaccines require ultra-cold storage (-70°C for certain Pfizer/BioNTech products), while plasma products demand temperature-controlled fractionation and distribution. The partner must demonstrate validated cold chain infrastructure from factory to point of administration.
• Pipeline alignment and technology platform compatibility: Evaluate whether the partner's manufacturing technology (mammalian cell culture, yeast expression, mRNA-LNP formulation, plasma fractionation) matches your product requirements. GSK's investment in AI-powered flexible biologics manufacturing signals platform adaptability that traditional fixed-purpose facilities lack.
• Financial stability and capital commitment: The partner must sustain multi-year, multi-billion-dollar manufacturing buildout programs. Roche's $50 billion US commitment, Lilly's $21+ billion Indiana investment, and Novo Nordisk's continuous Kalundborg expansion demonstrate the financial staying power required for biologic manufacturing partnerships.
For government and public health procurers specifically, evaluate pandemic preparedness capability: can the partner rapidly redirect production to a novel pathogen? Cell-based and mRNA vaccine platforms offer significantly faster strain-change timelines than traditional egg-based influenza manufacturing.
全球生物制品和疫苗市场在制造能力、监管框架、定价模式和疾病负担模式方面存在深刻的区域不对称。理解这些差异对于市场准入策略、供应链规划和竞争定位至关重要。
北美（美国和加拿大）：按价值计算的主导生物制品市场，约占全球生物制品销售额的45-50%。美国市场的特点是基于市场的定价（全球最高）、FDA监管领导地位（设定事实上的全球标准）以及最激进的制造回流趋势——辉瑞、礼来、罗氏、GSK、赛诺菲和默沙东共同承诺超过1500亿美元用于美国设施建设和扩建。《通胀削减法案》的药品价格谈判条款正在对传统生物制品施加新的定价压力。
欧洲：拥有全球十大生物制品制造商中的四家（丹麦的诺和诺德、法国的赛诺菲、瑞士的罗氏、德国的BioNTech）。欧洲市场的特点是EMA集中审批、通过联合招标进行集体采购，以及通常低于美国的价格。制造集中在丹麦（诺和诺德的卡伦堡综合体）、瑞士（罗氏的巴塞尔和龙沙的维斯普设施）和德国（BioNTech的美因茨总部），形成了具有专业劳动力池的区域供应链集群。
中国：全球第二大医药市场正在经历最剧烈的结构性转型。智飞生物因HPV疫苗库存积压损失147亿元人民币，标志着维持跨国疫苗收入数十年的“进口-分销”模式的终结。国内制造商（万泰生物、沃森生物）正在迅速缩小在HPV、肺炎球菌和mRNA疫苗方面的技术差距。中国的带量采购体系将定价压力扩展到生物制品，而监管改革正在加速国内创新。
新兴市场（印度、东南亚、非洲、拉丁美洲）：这些地区代表了最高的数量增长潜力，但也是最复杂的准入挑战。全球疫苗免疫联盟和联合国儿童基金会的采购机制主导着儿科疫苗的定价。CSL的300多个血浆采集中心遍布美国和欧洲，突显了血浆衍生制品制造在发达市场的集中。BioNTech在卢旺达部署模块化BioNTainer代表了“制造作为援助”的新模式，可能重塑低收入地区的疫苗供应。
The global biologics and vaccine market is shaped by profound regional asymmetries in manufacturing capability, regulatory frameworks, pricing models, and disease burden patterns. Understanding these differences is essential for market access strategy, supply chain planning, and competitive positioning.
North America (US and Canada): The dominant biologics market by value, accounting for approximately 45-50% of global biologic sales. The US market is characterized by market-based pricing (the highest globally), FDA regulatory leadership that sets de facto global standards, and the most aggressive manufacturing onshoring trend—Pfizer, Lilly, Roche, GSK, Sanofi, and Merck have collectively committed over $150 billion to US facility construction and expansion. The Inflation Reduction Act's drug price negotiation provisions are introducing new pricing pressure on legacy biologics.
Europe: Home to four of the top ten global biologics manufacturers (Novo Nordisk in Denmark, Sanofi in France, Roche in Switzerland, BioNTech in Germany). The European market features centralized EMA approval, collective procurement through joint tendering, and generally lower prices than the US. Manufacturing concentration in Denmark (Novo Nordisk's Kalundborg complex), Switzerland (Roche's Basel and Lonza's Visp facilities), and Germany (BioNTech's Mainz headquarters) creates regional supply chain clusters with specialized labor pools.
China: The world's second-largest pharmaceutical market is undergoing the most dramatic structural transition. Zhifei Biological's RMB 14.7 billion loss on stranded HPV vaccine inventory signals the end of the "import-and-distribute" model that sustained multinational vaccine revenues for decades. Domestic manufacturers (Wantai Biological, Walvax Biotechnology) are rapidly closing the technology gap in HPV, pneumococcal, and mRNA vaccines. China's Volume-Based Procurement (VBP) system extends pricing pressure to biologics, while regulatory reforms are accelerating domestic innovation.
Emerging markets (India, Southeast Asia, Africa, Latin America): These regions represent the highest volume growth potential but the most complex access challenges. Gavi, the Vaccine Alliance, and UNICEF procurement mechanisms dominate pricing for pediatric vaccines. CSL's 300+ plasma collection centers span the US and Europe, highlighting the concentration of plasma-derived product manufacturing in developed markets. BioNTech's modular BioNTainer deployment in Rwanda represents a novel "manufacturing as aid" model that could reshape vaccine supply in low-income regions.
